Dr Reddy’s Sells North American Rights For Celecoxib Oral Solution
As Company Partners With BioDelivery Sciences For Elyxyb
India’s Dr Reddy’s has sold the US and Canadian rights to its 25mg/ml Elyxyb (celecoxib) oral solution to US-based BioDelivery Sciences International, for an upfront payment of $6m, followed by $9m within one year from closing the deal.
You may also be interested in...
Asia Deal Watch: Incyte Inks Chinese Marketing Partnership With InnoCare For Monjuvi
Gracell and FutureGen and NovaRock and Flame partner in Claudin 18.2 antibody R&D for cancer. Plus deals involving HDT Bio/Quratis, Pfizer China/Ferring and Antengene/MindRank AI.
Dr Reddy’s Signals Reset In Europe
Dr Reddy’s enjoyed a strong showing in Europe in the fiscal fourth quarter amid a string of launches and a ramp-up in France, Italy and Spain, with the Indian firm anticipating continued momentum in the region by leveraging its global portfolio. The firm’s China growth strategy is 'still valid', management maintains.
Kelix Strikes A Deal To Acquire 14 Oncology Injectables
Kelix bio has announced two deals to expand its presence in Africa. The company is set to acquire 14 oncology injectable products from Germany-based Vitane. Furthermore, Kelix has acquired Pharmaceutical Institute, a pharmaceutical company established in Rabat, to enter Morocco. The pan-African company has also invested in Malta.